A Study of Ibandronate (Boniva) to Evaluate Bone Turnover Markers in Women With Treatment-Naive Postmenopausal Osteoporosis
A Prospective Open-Label, Multicenter Study to Evaluate the Change in Bone Turnover Markers After Once Monthly Oral Ibandronate Therapy in Treatment Naive Postmenopausal Osteoporosis Patients
Studieoversikt
Status
Status
Forhold
Forhold
Intervensjon / Behandling
Intervensjon / Behandling
Studietype
Studietype
Registrering (Faktiske)
Registrering
Fase
Fase
- Fase 4
Kontakter og plasseringer
Studiesteder
-
-
Alabama
-
Montgomery, Alabama, Forente stater, 36111
-
-
Arizona
-
Chandler, Arizona, Forente stater, 85225
-
Peoria, Arizona, Forente stater, 85381
-
-
Arkansas
-
Hot Springs, Arkansas, Forente stater, 71913
-
Pine Bluff, Arkansas, Forente stater, 71603
-
-
California
-
Anaheim, California, Forente stater, 92801
-
Beverly Hills, California, Forente stater, 90211
-
Carmichael, California, Forente stater, 95608
-
-
Delaware
-
Wilmington, Delaware, Forente stater, 19805
-
-
Florida
-
Deland, Florida, Forente stater, 32720
-
Miami, Florida, Forente stater, 33186
-
Miami, Florida, Forente stater, 33176
-
Palm Habor, Florida, Forente stater, 34684
-
Palm Springs, Florida, Forente stater, 33461
-
West Palm Beach, Florida, Forente stater, 33409
-
-
Georgia
-
Atlanta, Georgia, Forente stater, 30309
-
Rome, Georgia, Forente stater, 30165
-
-
Illinois
-
Morton Grove, Illinois, Forente stater, 60053
-
-
Indiana
-
Indianapolis, Indiana, Forente stater, 46202
-
-
Iowa
-
Waterloo, Iowa, Forente stater, 50702
-
-
Maryland
-
Baltimore, Maryland, Forente stater, 21209
-
Hagerstown, Maryland, Forente stater, 21740
-
Reistertown, Maryland, Forente stater, 21136
-
-
Mississippi
-
Olive Branch, Mississippi, Forente stater, 38654
-
-
Missouri
-
Jefferson City, Missouri, Forente stater, 65109
-
St Louis, Missouri, Forente stater, 63108
-
-
Nebraska
-
Omaha, Nebraska, Forente stater, 68131
-
-
New Jersey
-
Bloomfield, New Jersey, Forente stater, 07003
-
-
New York
-
Bronx, New York, Forente stater, 10461
-
New York, New York, Forente stater, 10016
-
-
North Carolina
-
Morehead City, North Carolina, Forente stater, 28557
-
Morganton, North Carolina, Forente stater, 28655
-
Raleigh, North Carolina, Forente stater, 27612
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Forente stater, 73112
-
-
Oregon
-
Medford, Oregon, Forente stater, 97504
-
-
Pennsylvania
-
Doylestown, Pennsylvania, Forente stater, 18901
-
Langhorne, Pennsylvania, Forente stater, 19047
-
Philadelphia, Pennsylvania, Forente stater, 19131
-
-
South Carolina
-
Mount Pleasant, South Carolina, Forente stater, 29464
-
Spartanburg, South Carolina, Forente stater, 29307
-
-
Tennessee
-
Morristown, Tennessee, Forente stater, 37813
-
Murfreesboro, Tennessee, Forente stater, 37130
-
Nashville, Tennessee, Forente stater, 37203
-
-
Texas
-
Amarillo, Texas, Forente stater, 79106
-
Fort Worth, Texas, Forente stater, 76101
-
San Antonio, Texas, Forente stater, 78229
-
Texarkana, Texas, Forente stater, 75503
-
-
Virginia
-
Richmond, Virginia, Forente stater, 23226
-
-
Washington
-
Tacoma, Washington, Forente stater, 98405
-
-
Wisconsin
-
Madison, Wisconsin, Forente stater, 53705
-
-
-
-
-
Ponce, Puerto Rico, 00717-1318
-
San Juan, Puerto Rico, 00935
-
San Juan, Puerto Rico, 00927
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
- Barn
- Voksen
- Eldre voksen
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Women newly diagnosed with postmenopausal osteoporosis
- Naive to prior bisphosphonate therapy
Exclusion Criteria:
- Inability to stand or sit upright for at least 60 minutes
- Inability to swallow a tablet whole
- Hypersensitivity to any component of ibandronate
- Hormone (estrogen) replacement therapy within last 3 months, or will start on therapy within next 6 months
- Other osteoporosis drug within last 3 months
- Malignant disease diagnosed within previous 10 years, except resected basal cell cancer
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Ikke-randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Antall våpen
Våpen og intervensjoner
Deltakergruppe / ArmDeltakergruppe / Arm |
Intervensjon / BehandlingIntervensjon / Behandling |
|---|---|
|
Eksperimentell: Ibandronate Group 1
Participants will receive a 6-month regimen with oral ibandronate, 150 mg once monthly.
Group 1 will receive a physician consultation after 4 months of treatment to review bone turnover test results.
|
Participants will receive oral ibandronate, 150 mg once weekly, for approximately 6 months.
Andre navn:
|
|
Eksperimentell: Ibandronate Group 2
Participants will receive a 6-month regimen with oral ibandronate, 150 mg once monthly.
Group 2 will not receive a physician consultation.
|
Participants will receive oral ibandronate, 150 mg once weekly, for approximately 6 months.
Andre navn:
|
Hva måler studien?
Primære resultatmål
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Percent Change From Baseline to Month 6 in Serum C-terminal Telopeptide of Type 1 Collagen (CTX)
Tidsramme: Baseline, Month 6
|
Serum CTX is a measure of bone resorption and is measured as nanograms per milliliter (ng/mL).
Percent change from Baseline to Month 6 was calculated using Month 6 value minus baseline value divided by baseline value, and then multiplied by 100.
Data for this outcome measure was reported for all participants combined (Consult group plus Non-consult group).
|
Baseline, Month 6
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Percent Change From Baseline to Month 6 in Urine N-terminal Telopeptide of Type 1 Collagen (NTX)
Tidsramme: Baseline, Month 6
|
Urine NTX is a measure of bone resorption and is measured as millimoles bone collagen equivalents per millimoles creatinine.
Percent change from baseline to Month 6 was calculated using Month 6 value minus baseline value divided by baseline value, and then multiplied by 100.
Data for this outcome measure was reported for all participants combined (Consult group plus Non-consult group).
|
Baseline, Month 6
|
|
Percent Change From Baseline to Month 6 in Serum Procollagen Type 1 N-terminal Propeptide (P1NP)
Tidsramme: Baseline, Month 6
|
Serum P1NP is a measure of bone resorption and is measured as ng/mL.
Percent change from baseline to Month 6 was calculated using Month 6 value minus Baseline value divided by baseline value, and then multiplied by 100.
Data for this outcome measure was reported for all participants combined (Consult group plus Non-consult group).
|
Baseline, Month 6
|
|
Percent Change From Baseline to Month 6 in Serum Osteocalcin
Tidsramme: Baseline, Month 6
|
Serum osteocalcin is a measure of bone resorption and is measured as ng/mL.
Percent change from baseline to Month 6 was calculated using Month 6 value minus baseline value divided by baseline value, and then multiplied by 100.
Data for this outcome measure was reported for all participants combined (Consult group plus Non-consult group).
|
Baseline, Month 6
|
|
Percent Change From Baseline to Month 6 in Serum Bone-Specific Alkaline Phosphatase (BSAP)
Tidsramme: Baseline, Month 6
|
Serum BSAP is a measure of bone resorption and is measured as ng/mL.
Percent change from baseline to Month 6 was calculated using Month 6 value minus baseline value divided by baseline value, and then multiplied by 100.
Data for this outcome measure was reported for all participants combined (Consult group plus Non-consult group).
|
Baseline, Month 6
|
|
Percentage of Participants Who Were "Very Confident" or "Confident" to Items on the Boniva Confidence Scale (BCS) at Month 6
Tidsramme: Month 6
|
The BCS is designed to measure the participant's confidence level that Boniva (ibandronate) therapy is effective in treating osteoporosis and reducing the risk of fracture.
Response options ranged on a 5-point scale from 'Not At All Confident' to 'Very Confident.'
A Boniva confidence responder was defined as a participant who reported a response of 'confident' or 'very confident' on the 2 items in BCS.
(1) ibandronate was effective in treating osteoporosis and (2) ibandronate reduces the risk of breaking a bone.
|
Month 6
|
Samarbeidspartnere og etterforskere
Sponsor
Sponsor
Studierekorddatoer
Studer hoveddatoer
Studiestart
Studiestart
Primær fullføring (Faktiske)
Primær fullføring
Studiet fullført (Faktiske)
Studiet fullført
Datoer for studieregistrering
Først innsendt
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Først lagt ut
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
Sist oppdatering lagt ut
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
Andre studie-ID-numre
- ML18057
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .